Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.

Not Applicable

Completed

Conditions: Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy

First Posted Date: 2006-06-16

Last Posted Date: 2006-06-23

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 22

Registration Number: NCT00337623

Locations: 🇫🇷
Clermont-Ferrand University Hospital, Clermont-Ferrand, Auvergne, France

Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: Prednisolone
Procedure: Bronchoscopy

First Posted Date: 2006-05-18

Last Posted Date: 2017-08-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 47

Registration Number: NCT00327197

Locations: 🇬🇧
GSK Investigational Site, Leicester, Leicestershire, United Kingdom

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-04-24

Last Posted Date: 2015-09-25

Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

Target Recruit Count: 96

Registration Number: NCT00317408

Locations: 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪
Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans

Phase 4

Completed

Conditions: Regional Blood Flow
Optic Disk

First Posted Date: 2006-04-10

Last Posted Date: 2006-04-10

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 24

Registration Number: NCT00312325

Locations: 🇦🇹
Department of Clinical Pharmacology, Vienna, Austria

Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy

Phase 3

Completed

Conditions: Hemangiomas

First Posted Date: 2006-04-10

Last Posted Date: 2018-04-19

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 20

Registration Number: NCT00312520

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Prednisolone
Drug: COLAL-PRED®

First Posted Date: 2006-03-06

Last Posted Date: 2008-04-25

Lead Sponsor: Alizyme

Target Recruit Count: 796

Registration Number: NCT00299013

Locations: 🇭🇺
Fejer Megyei Szent Gyorgy Korhaz, Székesfehérvár, Hungary
🇨🇿
Gastroenterologicka ambulance, Hradec Kralove, Czech Republic
🇨🇿
Hepato-Gastroenterologie HK s.r.o., Hradec Kralove, Czech Republic

and more 51 locations

Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

Not Applicable

Completed

Conditions: Childhood Langerhans Cell Histiocytosis

First Posted Date: 2006-01-13

Last Posted Date: 2014-01-10

Lead Sponsor: Histiocyte Society

Target Recruit Count: 376

Registration Number: NCT00276757

Locations: 🇬🇧
Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom

and more 29 locations

Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

First Posted Date: 2006-01-11

Last Posted Date: 2013-07-10

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 600

Registration Number: NCT00275106

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧
Royal Manchester Children's Hospital, Manchester, England, United Kingdom
🇩🇪
Kinderklinik, Giessen, Germany

and more 18 locations

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Transdermal Oestradiol
Drug: Prednisolone
Drug: Celecoxib
Drug: Docetaxel
Drug: ADT
Radiation: Radiotherapy to the prostate
Drug: Zoledronic Acid
Drug: Metformin
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2005-12-22

Last Posted Date: 2023-04-18

Lead Sponsor: Medical Research Council

Target Recruit Count: 11992

Registration Number: NCT00268476

Locations: 🇬🇧
West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom
🇬🇧
Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧
Russells Hall Hospital, Dudley, England, United Kingdom

and more 115 locations

Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients

Phase 4

Completed

Conditions: Graft Rejection
Kidney Failure
Kidney Transplantation

First Posted Date: 2005-12-05

Last Posted Date: 2006-05-19

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 160

Registration Number: NCT00261820

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy